⚠ Evidence warning: Clinical trials or other evidence do not support the claim that ultra-long GnRH agonist pre-treatment improves implantation and live-birth rates compared with standard IVF protocols. This page keeps it as a report of what people, websites or other media say.

Endometriosis and Adenomyosis — the Cousin Condition

Adenomyosis Overlap — scientific infographic poster

Table of Contents

  1. What Adenomyosis Is
  2. How Often Endo and Adeno Overlap
  3. Symptoms — and Why Attribution Is Hard
  4. Why the Overlap Matters
  5. Diagnosis — Magnetic Resonance Imaging as the Non-Invasive Gold Standard
  6. Sonographic Features and the MUSA Criteria
  7. Clinical Signs Felt on a Pelvic Exam
  8. Subtypes: Diffuse vs Focal Adenomyoma
  9. Treatment Differences from Endometriosis
  10. Hysterectomy — the Only Definitive Cure
  11. Fertility and IVF Considerations
  12. Why an Excision Surgeon Alone Isn't Enough
  13. Pregnancy with Adenomyosis
  14. Choosing Medical vs Surgical Management
  15. When to Suspect Adenomyosis If You Have Endo
  16. Key Research Papers
  17. Connections
  18. Featured Videos

What Adenomyosis Is

Adenomyosis is endometrial tissue — the same glands and stroma that line the inside of your uterus and shed every month as a period — growing inside the muscular wall of the uterus itself (the myometrium). That is the entire distinction from endometriosis in one sentence. Endometriosis: endometrial-like tissue outside the uterus, seeded on ovaries, peritoneum, bowel, bladder, diaphragm. Adenomyosis: the same kind of tissue burrowing into the uterine muscle.

The practical consequence is dramatic. In endometriosis, the implants bleed into the pelvis and trigger scarring, adhesions, and nerve inflammation in places they should not be. In adenomyosis, the implants bleed inside the uterine muscle, which has nowhere to drain. Each cycle, microscopic pockets of trapped blood swell, the surrounding muscle hypertrophies in response, and the uterus becomes progressively bulky, boggy, and hypercontractile. The resulting periods are not just painful — they are heavy, flooding, and accompanied by cramping that feels deeper and more internal than classic endo pain.

The two diseases share a suspected origin in the junction between endometrium and myometrium (the so-called junctional zone), share estrogen dependence, share response to hormonal suppression, and very often share a patient. They are close enough to be called cousins, and different enough that treating one and ignoring the other leaves half the problem behind.

How Often Endo and Adeno Overlap

The numbers that matter, because they change how a diagnosis of either disease is read:

Read those numbers again. Nearly half of all endometriosis patients have a second, structurally different disease sitting inside the uterus. If you have been told you "just" have endo and your uterus still hurts, those statistics are the first clue that the picture may be incomplete.

Symptoms — and Why Attribution Is Hard

Classic adenomyosis symptoms cluster into four areas:

The attribution problem is obvious: every one of those symptoms overlaps with endometriosis. A patient with both diseases cannot, by symptom history alone, tell her doctor which disease is doing what. This is exactly where imaging earns its keep.

Why the Overlap Matters

Here is the scenario that plays out in gynecology clinics every week. A patient with textbook endometriosis undergoes a skilled excision surgery. Every lesion is mapped, excised, and pathologically confirmed. She recovers, and for a few months things are better. Then the heavy bleeding returns. The deep cramping returns. She returns to her excision surgeon in tears, certain the endo has grown back.

In many of those cases, the endo did not grow back. It was never what was causing the uterine pain and flooding periods in the first place. The second disease — adenomyosis — was untouched by the excision surgery because it lives inside the uterine wall, which the excision surgeon (correctly) did not cut into. The only way to prevent this outcome is to know before surgery that both diseases are present, so both can be planned for.

This is the reason a dedicated look at the uterus is described as part of a full endometriosis workup: not a quick pelvic ultrasound at the end of a routine visit, but a focused look at the uterine wall by someone who knows what adenomyosis looks like.

Diagnosis — Magnetic Resonance Imaging as the Non-Invasive Gold Standard

Pelvic magnetic resonance imaging is the most reliable non-invasive test for adenomyosis. A good radiology protocol uses T2-weighted sequences to visualize the three uterine layers: the inner endometrium, the thin junctional zone (the inner myometrium), and the outer myometrium. In a healthy uterus, the junctional zone is a thin dark band measuring under 8 mm.

The magnetic resonance imaging findings that establish adenomyosis:

Magnetic resonance imaging also stages any coexisting deep infiltrating endometriosis — uterosacral nodules, bladder and bowel involvement, endometriomas — in the same scan. Because one scan covers both diseases, pelvic magnetic resonance imaging with an endometriosis-and-adenomyosis protocol gives the most information from a single imaging study before major surgery. Reading these scans is a pattern-recognition skill, and radiologists who read pelvic magnetic resonance imaging routinely are the most practised at it.

Sonographic Features and the MUSA Criteria

High-resolution transvaginal ultrasound (TVUS) in expert hands rivals magnetic resonance imaging for adenomyosis diagnosis and costs a fraction of the price. In 2015 an international group published the Morphological Uterus Sonographic Assessment (MUSA) consensus criteria, which standardize what sonographers should look for and how to report it. The MUSA features:

The catch is the operator. A quick ultrasound by a general obstetrician-gynecologist (OB/GYN) at the end of a visit routinely misses adenomyosis. Sonographers and sonologists trained in MUSA reporting work mostly at academic centers, dedicated endometriosis imaging practices and reproductive imaging clinics; whether a scan uses the MUSA criteria is something an imaging center can say before the appointment is booked.

Clinical Signs Felt on a Pelvic Exam

On a bimanual pelvic exam, adenomyosis often produces a classic finding: a symmetrically enlarged, boggy, tender uterus. "Boggy" is the word experienced clinicians use for a uterus that feels softer and more yielding than normal, as if the muscle is waterlogged — which, in a sense, it is. Compare this with a fibroid uterus, which feels firm and knobby, or a normal uterus, which feels firm and walnut-shaped.

Most adenomyosis shows up in the 30s and 40s, often after childbirth, with symptoms peaking in the decade before menopause. This is an important generational shift from endometriosis, which classically begins in the teens and twenties. An endo patient who had manageable disease in her twenties and now, at 38, faces newly catastrophic periods has not necessarily had her endo worsen — she may have developed adenomyosis on top of it. That said, adolescent and early-twenties adenomyosis is now recognized more often with better imaging, so age alone never excludes the diagnosis.

Subtypes: Diffuse vs Focal Adenomyoma

Adenomyosis comes in two structural patterns, which matter because they respond differently to surgery:

Some patients have both: a diffuse background with a dominant focal nodule. An expert magnetic resonance imaging report will describe which pattern is present, which is critical pre-operative information.

Treatment Differences from Endometriosis

Adenomyosis and endometriosis share some therapies and differ sharply on others. The overlap and the divergences:

Levonorgestrel Intrauterine System — First-Line

The 52 mg levonorgestrel intrauterine system (a hormonal intrauterine device, IUD) is the single most effective conservative therapy for adenomyosis and in most guidelines is the first-line recommendation. Local progestin thins and atrophies the ectopic endometrium inside the muscle. Studies show the majority of patients experience substantial pain reduction and roughly 60–80% progress to amenorrhea (no periods) within a year. On the U.S. drug label, the 52 mg system is approved to prevent pregnancy for up to 8 years and to treat heavy menstrual bleeding for up to 5 years; the label lists no adenomyosis indication. For many patients, the levonorgestrel system avoids hysterectomy entirely.

A 2026 meta-analysis of 8 studies (527 patients: 277 with the levonorgestrel system, 250 taking dienogest tablets) found no difference between the two in period pain, uterine size or menstrual blood loss at 3 and 6 months. At 12 months, one study found that the levonorgestrel system shrank the uterus more while dienogest eased period pain more. The authors noted that only 8 studies were available and called for larger randomized trials.

Continuous Hormonal Suppression

Same as endometriosis: continuous combined oral contraceptives, norethindrone acetate, dienogest, or depot medroxyprogesterone acetate (DMPA) injections. Stopping ovulation and the monthly hormonal cycle quiets both diseases simultaneously. This is an attractive option when a patient has both conditions and wants one therapy that treats both.

Gonadotropin-Releasing Hormone (GnRH) Antagonists

Elagolix and relugolix combination therapy (approved for uterine fibroids and endometriosis-associated pain) can be used off-label for adenomyosis with good symptomatic response. They suppress ovarian estrogen production and typically include low-dose add-back hormones to protect bone. Treatment is often limited to two years.

Uterine Artery Embolization (UAE)

Interventional radiologists thread a catheter into the uterine arteries and inject particles that cut off blood flow to the diseased muscle. The ectopic endometrium shrinks. UAE works for both diffuse and focal adenomyosis and avoids surgery. Fertility implications are mixed — pregnancies after UAE are possible but carry increased risks of placentation abnormalities and preterm delivery, so UAE is generally reserved for patients who have completed childbearing.

Adenomyomectomy

Surgical excision of a focal adenomyoma, preserving the uterus. This is a difficult operation with no clean surgical plane (unlike a fibroid, which shells out of a capsule). Only a handful of surgeons worldwide do it routinely. Post-operative pregnancy is possible but carries a meaningful risk of uterine rupture, and most centers mandate cesarean delivery. Reserved for patients with focal disease who want to preserve fertility.

Hysterectomy

The one definitive cure. Discussed in its own section below.

Hysterectomy — the Only Definitive Cure

Because adenomyosis lives inside the uterine muscle itself, removing the uterus is the only way to guarantee the disease is gone. For women who have completed childbearing and whose adenomyosis remains severe despite medical therapy, hysterectomy is often chosen and is the option that restores quality of life most reliably.

Key choices within the operation:

Hysterectomy for adenomyosis, done well and with ovaries preserved, has one of the highest patient-satisfaction rates of any gynecologic procedure.

Fertility and IVF Considerations

Adenomyosis reduces fertility by two mechanisms: distorted uterine contractility (abnormal peristalsis that interferes with sperm transport and embryo implantation) and a hostile junctional-zone environment. In vitro fertilization (IVF) outcomes in untreated adenomyosis are meaningfully lower than in matched controls.

A widely used protocol is ultra-long GnRH agonist pre-treatment: three to six months of monthly leuprolide injections before embryo transfer, intended to shrink adenomyotic lesions, reduce uterine inflammation, and normalize the junctional zone. Studies consistently show improved implantation and live-birth rates with this approach compared with standard IVF protocols. It is a common practice whose benefit has not been shown in pooled studies, most of which were retrospective:

Focal adenomyoma may be a candidate for pre-pregnancy excision if it distorts the uterine cavity or is very large. Diffuse disease is treated medically rather than surgically before IVF.

Why an Excision Surgeon Alone Isn't Enough

Excision surgery is transformative for endometriosis. It is also, by itself, insufficient for a patient who also has adenomyosis. The mental model to carry into your consultations: excision handles the disease outside the uterus, and a separate decision — medical suppression, IUD, UAE, or hysterectomy — handles the disease inside the uterus.

A careful pre-operative workup therefore includes a look at the uterine wall itself. When imaging shows adenomyosis, a surgical plan can address both conditions: either by combining excision with a uterus-sparing adenomyosis therapy (a levonorgestrel intrauterine system placed at surgery, post-operative suppression) or, if adenomyosis is severe and childbearing is complete, by combining excision with hysterectomy in a single operation. Many excision surgeons are comfortable doing both. Others partner with a second gynecologic surgeon. Either way, a complete plan names the adenomyosis out loud before the anesthetic.

Pregnancy with Adenomyosis

Adenomyosis is compatible with pregnancy but carries measurable obstetric risks. Published data point to:

The largest pooled analysis so far, the 2026 ADELIN meta-analysis, combined 39 studies covering 25,564 women with adenomyosis. Compared with women without it, those with adenomyosis had higher risks of preeclampsia (about 2.2 times), miscarriage (1.6 times), heavy bleeding after birth (1.7 times), a low-lying or misplaced placenta (3.3 times) and very early (extreme preterm) birth (3.7 times). It found no significant difference for gestational diabetes, uterine rupture or stillbirth (intrauterine death). The authors rated the certainty of this evidence low to very low.

These risks do not rule out pregnancy. The care described for them includes co-management with a maternal-fetal medicine specialist, extra attention to cervical length surveillance in the second trimester, a delivery plan at a hospital equipped for postpartum hemorrhage, and careful third-stage management (active management of the placenta with uterotonics on hand).

Choosing Medical vs Surgical Management

The factors that usually shape the decision:

When to Suspect Adenomyosis If You Have Endo

Signs that point toward adenomyosis in someone who already has an endometriosis diagnosis:

The tests that look specifically for adenomyosis are a pelvic magnetic resonance imaging with an adenomyosis protocol and a transvaginal ultrasound by an operator trained in the MUSA criteria, rather than a generic scan.

Key Research Papers

  1. Van den Bosch T, et al. Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group. Ultrasound Obstet Gynecol. 2015. — doi:10.1002/uog.14806
  2. Chapron C, et al. Diagnosing adenomyosis: an integrated clinical and imaging approach. Hum Reprod Update. 2020. — doi:10.1093/humupd/dmz049 (Overlap with endometriosis.)
  3. Vannuccini S, Petraglia F. Recent advances in understanding and managing adenomyosis. F1000Res. 2019;8:283. — doi:10.12688/f1000research.17242.1
  4. ESHRE Endometriosis Guideline Group. ESHRE guideline: endometriosis. Hum Reprod Open. 2022. — doi:10.1093/hropen/hoac009
  5. Woodward KT, Burnett TL, Khan Z, Cole KC, VanBuren WM, Schoolmeester JK, Green IC, Cope AG. Prevalence of concomitant endometriosis in patients undergoing laparoscopic hysterectomy with suspected adenomyosis: a retrospective cohort study. Eur J Obstet Gynecol Reprod Biol. 2026;323:115126. — PubMed PMID: 42066596
  6. Etrusco A, Agrifoglio V, D'Amato A, De Nigris A, Leone Roberti Maggiore U, Di Donna MC, Riemma G, Cozzolino M. The ADELIN analysis: the presence of ADenomyosis and its effects on matErnal, neonataL, and obstetrIc outcomes: a systematic review and meta-aNalysis. Am J Obstet Gynecol. 2026;234(4):919-979. — PubMed PMID: 41232787
  7. Su S, Xue H, Bai X, Li J, Zhang Z. Comparison Between Levonorgestrel-Releasing Intrauterine Device and Dienogest for Adenomyosis: A Systematic Review with Meta-Analysis. J Obstet Gynaecol Can. 2026;48(2):103147. — PubMed PMID: 41135726
  8. Steinmann M, Anthon C, Kohl Schwartz AS, Mackens S, Blockeel C, Kalaitzopoulos DR, Vidal A. GnRH agonist pretreatment prior to frozen embryo transfer in women with adenomyosis: a systematic review and meta-analysis. Reprod Biomed Online. 2025;51(5):105075. — PubMed PMID: 41075426
  9. González-Comadran M, Olmos EA, Mariño MAA, Vizcaíno MAC. Utility of GnRH Agonists before embryo transfer in women with adenomyosis: Systematic review and meta-analysis. JBRA Assist Reprod. 2025;29(3):507-519. — PubMed PMID: 40674550

PubMed Topic Searches

For further reading, the following PubMed topic searches return current peer-reviewed work on adenomyosis, its overlap with endometriosis, and its treatment:

  1. PubMed: Adenomyosis and endometriosis overlap
  2. PubMed: Adenomyosis MRI diagnosis and junctional zone
  3. PubMed: MUSA ultrasound criteria for adenomyosis
  4. PubMed: Levonorgestrel IUD for adenomyosis
  5. PubMed: Adenomyomectomy and fertility outcomes
  6. PubMed: Uterine artery embolization for adenomyosis
  7. PubMed: Adenomyosis, IVF, and ultra-long GnRH protocols
  8. PubMed: Adenomyosis and obstetric outcomes in pregnancy

Back to Table of Contents

Connections

Back to Table of Contents